NGM Biopharmaceuticals, Inc.
NGM · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $59 | $51 | $53 | $68 |
| Short-Term Investments | $88 | $115 | $140 | $163 |
| Receivables | $0 | $0 | $1 | $1 |
| Inventory | $0 | $0 | $1 | $1 |
| Other Curr. Assets | $9 | $8 | $9 | $9 |
| Total Curr. Assets | $156 | $177 | $204 | $243 |
| Property Plant & Equip (Net) | $7 | $8 | $9 | $10 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $2 | $2 | $2 | $2 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $3 | $5 | $5 | $4 |
| Total NC Assets | $12 | $15 | $16 | $16 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $169 | $192 | $221 | $259 |
| Liabilities | – | – | – | – |
| Payables | $3 | $5 | $6 | $13 |
| Short-Term Debt | $0 | $1 | $3 | $4 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $1 | $0 |
| Other Curr. Liab. | $17 | $16 | $19 | $20 |
| Total Curr. Liab. | $20 | $22 | $28 | $38 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $17 |
| Other Liabilities | $0 | $0 | $0 | -$17 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $20 | $22 | $28 | $38 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$724 | -$696 | -$668 | -$629 |
| AOCI | $0 | -$0 | -$0 | -$0 |
| Other Equity | $873 | $866 | $860 | $850 |
| Total Equity | $149 | $170 | $192 | $221 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $169 | $192 | $221 | $259 |
| Net Debt | -$59 | -$50 | -$51 | -$63 |